ABANZA designs and commercializes soft tissue fixation products, led by its WasherCap™ Fixation System which has FDA clearance for fixation of soft tissue grafts including tendons and ligaments in procedures such as ACL reconstruction. The company completed a preliminary launch with a select group of surgeons and is preparing to introduce the WasherCap™ Mini for additional applications in the knee, hand, wrist, and elbow. ABANZA plans to accelerate its U.S. market entry and expand its field sales team to work with leading orthopedic specialists across key U.S. markets. The company intends to scale staffing, production capacity, and physician education efforts as part of its rollout. ABANZA emphasizes its patented technology to enhance fixation strength regardless of patient bone quality and to minimize graft displacement after surgery. The company is positioning the WasherCap™ line as the lead product in a broader strategy of soft tissue repair solutions. Abanza Tecnomed designs and develops medical devices and surgical instrumentation focused on sports medicine and arthroscopic procedures. Its first product, the WasherCap, is an innovative soft‑tissue fixation system for anterior cruciate ligament (ACL) reconstruction and has obtained CE marking. The company received authorization to commercialize the WasherCap in Europe on 29 January and has also secured ISO 13485 certification for medical‑device manufacturing. Abanza won the Everis Global Award in 2019 and says it will continue R&D in the arthroscopic field while preparing product launch and internationalization. Management frames the market opportunity around the high prevalence of ACL injuries and aims to position the company as a reference in minimally invasive sports‑medicine solutions. Abanza Tecnomed develops medical devices and surgical instruments for sports medicine and traumatology, having created an innovative tibial fixation device for anterior cruciate ligament (ACL) arthroscopic surgery. The new arthroscopic solution aims to address key shortcomings of existing soft‑tissue implant techniques. Clinical trials are planned imminently with Clínica Universidad de Navarra (CUN) and the Arthroscopic Surgery Unit of Hospital Vithas San José de Vitoria, which supported the project during design phases. The company’s stated goals are higher surgeon and patient success rates, fewer reoperations, earlier and less painful rehabilitation, and reduced risk of osteoarthritis (reported to affect 57% of operated ACL patients). Abanza intends to commercialize this tibial fixation device and other arthroscopic systems currently in development. Financially, the company has secured financing commitments to pursue its business plan, including a contribution from UN I+D+i Tech Transfer together with co‑investors.

Total raised

$6M

Funding rounds

3

Latest round

Series A

Latest activity

Sep 2024